ImmuPharma PLC (GB:IMM)
LSE:IMM
Top Page
ImmuPharma
(LSE:IMM)
Select Model
Select Model
Rating:46Neutral
Price Target:
6.00 p
▼(-3.23% Downside)
Action:ReiteratedDate:01/08/26
The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.
Positive Factors
Low leverage / minimal debt
Near-zero reported debt reduces fixed interest costs and financial distress risk, preserving flexibility. For a clinical-stage biotech this allows management to prioritize R&D and partner negotiations without immediate debt servicing constraints, supporting longer-term program funding options.
Negative Factors
Absent recurring revenue
A near-zero revenue base removes any recurring cash cushion and makes the company wholly dependent on milestone, partner payments or financings. This structurally limits self‑funding capacity and increases execution risk if anticipated transactions or partnerships do not materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / minimal debt
Near-zero reported debt reduces fixed interest costs and financial distress risk, preserving flexibility. For a clinical-stage biotech this allows management to prioritize R&D and partner negotiations without immediate debt servicing constraints, supporting longer-term program funding options.
Read all positive factors
ImmuPharma (IMM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£22.87M
Dividend YieldN/A
Average Volume (3M)15.00M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding502,723,940
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-9.23
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidat...
How the Company Makes Money
ImmuPharma’s primary way of generating revenue is through the business model typical of clinical-stage biopharmaceutical companies: progressing proprietary drug candidates and seeking monetization via partnering and transaction-based income rather...
ImmuPharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 118.35K | 126.67K |
| Gross Profit | -73.56K | -63.88K | -37.61K | -118.00K | 118.35K | 126.67K |
| EBITDA | -3.07M | -2.61M | -3.02M | -2.91M | -8.70M | -6.84M |
| Net Income | -3.93M | -2.48M | -2.92M | -3.81M | -8.17M | -6.86M |
Balance Sheet | ||||||
| Total Assets | 1.58M | 977.01K | 2.72M | 3.97M | 6.00M | 10.92M |
| Cash, Cash Equivalents and Short-Term Investments | 396.65K | 236.90K | 208.48K | 667.81K | 1.65M | 5.86M |
| Total Debt | 0.00 | 0.00 | 0.00 | 111.00 | 700.00 | 641.84K |
| Total Liabilities | 1.24M | 1.52M | 1.67M | 1.45M | 1.58M | 1.26M |
| Stockholders Equity | 336.70K | -542.86K | 1.06M | 2.52M | 4.41M | 9.65M |
Cash Flow | ||||||
| Free Cash Flow | -1.90M | -1.77M | -1.36M | -2.45M | -4.88M | -3.69M |
| Operating Cash Flow | -1.90M | -1.77M | -1.36M | -2.35M | -4.83M | -3.33M |
| Investing Cash Flow | -273.37K | 1.29M | 188.76K | -77.42K | -50.28K | -569.20K |
| Financing Cash Flow | 2.09M | 500.02K | 722.10K | 1.55M | 702.05K | 8.37M |
ImmuPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £121.94M | -4.45 | 90.29% | ― | ― | -94.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £29.09M | -1.92 | -53.86% | ― | ― | ― | |
47 Neutral | £64.58M | -0.27 | -3931.14% | ― | ― | ― | |
46 Neutral | £22.87M | -3.00 | 3817.30% | ― | ― | ― | |
44 Neutral | £22.78M | -3.13 | -202.14% | ― | ― | 23.76% | |
43 Neutral | £20.73M | -54.98 | -10.01% | ― | 283.74% | 78.57% |
* Healthcare Sector Average
GB:IMM
ImmuPharma
4.55
1.36
42.63%
GB:SAR
Sareum Holdings
16.50
4.50
37.50%
GB:SCLP
Scancell Holdings
11.75
3.50
42.42%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
1,005.00
813.75
425.49%
GB:SBTX
SkinBioTherapeutics
8.00
-15.25
-65.59%
GB:POLB
Poolbeg Pharma Ltd.
4.13
1.38
50.00%
ImmuPharma Corporate Events
Private Placements and Financing
ImmuPharma Launches £1.5m WRAP Retail Share Offer Alongside £7.5m Subscription
Neutral
Mar 17, 2026
ImmuPharma has launched a retail equity offer via the Winterflood Retail Access Platform to raise up to £1.5 million by issuing 25 million new ordinary shares at 6 pence each, matching the price of a separate £7.5 million institutional s...
Business Operations and StrategyPrivate Placements and Financing
ImmuPharma raises up to £7.5m to fast‑track Kapiglucagon as P140 licensing talks advance
Positive
Mar 17, 2026
ImmuPharma has secured a £6 million equity subscription from long‑term investor Lanstead Capital at 6 pence per share, with a further £1.5 million to be offered via a UK retail WRAP offer, to accelerate development of Kapiglucagon ...
Business Operations and Strategy
ImmuPharma Targets Investor Visibility at JP Morgan Conference and Biotech Showcase
Positive
Jan 6, 2026
ImmuPharma announced that its senior leadership team, including the CEO, COO and CSO, will attend the JP Morgan Healthcare Conference and the Biotech Showcase in San Francisco from 12–14 January 2026. Participation in these high-profile inve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.